CO6220957A2 - 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid - Google Patents

4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid

Info

Publication number
CO6220957A2
CO6220957A2 CO09099807A CO09099807A CO6220957A2 CO 6220957 A2 CO6220957 A2 CO 6220957A2 CO 09099807 A CO09099807 A CO 09099807A CO 09099807 A CO09099807 A CO 09099807A CO 6220957 A2 CO6220957 A2 CO 6220957A2
Authority
CO
Colombia
Prior art keywords
treatment
compound
symptoms
xrpd
norepinefrine
Prior art date
Application number
CO09099807A
Other languages
English (en)
Inventor
Tine Bryan Stensbol
Silke Miller
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CO6220957A2 publication Critical patent/CO6220957A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

1.- Un método para el tratamiento del ADHD, melancolía, depresión resistente al tratamiento o síntomas residuales en la depresión, comprendiendo el método la administración, de una cantidad terapéuticamente efectiva de 4-[2-(4-metifenilsulfanil)fenil]piperidina y sales de adición de ácidos de la misma (compuesto I) a un paciente que lo necesita. 2.- El método de acuerdo con la reivindicación 1 en donde compuesto l es la sal de adición de HBr. 3.- El método de acuerdo con la reivindicación 2, en donde el compuesto 1 está caracterizado por picos en un XRPD a aproximadamente 6,08, 14,81, 19,26 y 25,38°2?. 4.- El método de acuerdo con la reivindicación 3, en donde el compuesto l está caracterizado por un XRPD según se representa en la Figura 1. 5.- El método de acuerdo con cualquiera de las reivindicaciones 1-4, en donde el compuesto I se administra a 5-60 mg/día. 6.- Uso de 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sales de adición de ácidos de la misma (compuesto I) en la elaboración de un medicamento para el tratamiento del ADHD, melancolía, depresión resistente al tratamiento o síntomas residuales en la depresión. 7.- Uso de acuerdo con la reivindicación 6, en donde compuesto I es la sal de adición de HBr. 8.- Uso de acuerdo con la reivindicación 7, en donde el compuesto I está caracterizado por picos en un XRPD a aproximadamente 6,08, 14,81, 19,26 y 25,38°2?. 9.- Uso de acuerdo con la reivindicación 8, en donde el compuesto I está caracterizado por un XRPD según se representa en la Figura 1. 10.- Uso de acuerdo con cualquiera de las reivindicaciones 6-9, en donde dicho medicamento está destinado para la administración a 5-60 mg/día. 11.- 4-[2-(4-metilfenilsulfanil)fenil]piperidina y sales de adición de ácidos de la misma para usar en el tratamiento del ADHD, melancolía, depresión resistente al tratamiento o síntomas residuales en la depresión. 12.- El compuesto de acuerdo con la reivindicación 11, cuyo compuesto es la sal de adición de HBr. 13.- El compuesto de acuerdo con la reivindicación 12, cuyo compuesto está caracterizado por picos en un XRPD a aproximadamente 6,08, 14,81, 19,26 y 25,38°2?.
CO09099807A 2007-03-20 2009-09-15 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid CO6220957A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain

Publications (1)

Publication Number Publication Date
CO6220957A2 true CO6220957A2 (es) 2010-11-19

Family

ID=39575680

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09099807A CO6220957A2 (es) 2007-03-20 2009-09-15 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid

Country Status (28)

Country Link
US (2) US20100144788A1 (es)
EP (2) EP2139479B1 (es)
JP (1) JP5388867B2 (es)
KR (1) KR20090125775A (es)
CN (2) CN101646438B (es)
AR (1) AR065798A1 (es)
AU (1) AU2008228639B2 (es)
BR (1) BRPI0808831A2 (es)
CA (1) CA2684556C (es)
CL (1) CL2008000796A1 (es)
CO (1) CO6220957A2 (es)
CY (2) CY1113965T1 (es)
DK (2) DK2139479T3 (es)
EA (1) EA017407B1 (es)
ES (2) ES2399305T3 (es)
HK (1) HK1142007A1 (es)
HR (1) HRP20130049T1 (es)
IL (1) IL200954A (es)
MX (1) MX2009009934A (es)
MY (1) MY163537A (es)
NZ (1) NZ579723A (es)
PL (2) PL2139479T3 (es)
PT (2) PT2139479E (es)
RS (2) RS52676B (es)
SI (1) SI2139479T1 (es)
TW (1) TWI432194B (es)
UA (2) UA97660C2 (es)
WO (1) WO2008113360A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
SI2167085T1 (sl) * 2007-06-15 2014-05-30 H. Lundbeck A/S 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
JP5787881B2 (ja) * 2010-04-30 2015-09-30 武田薬品工業株式会社 腸溶性錠剤
US9311462B1 (en) 2011-03-04 2016-04-12 Zynga Inc. Cross platform social networking authentication system
US8332488B1 (en) 2011-03-04 2012-12-11 Zynga Inc. Multi-level cache with synch
US10135776B1 (en) 2011-03-31 2018-11-20 Zynga Inc. Cross platform social networking messaging system
US8347322B1 (en) 2011-03-31 2013-01-01 Zynga Inc. Social network application programming interface
US8522137B1 (en) 2011-06-30 2013-08-27 Zynga Inc. Systems, methods, and machine readable media for social network application development using a custom markup language
KR20190025556A (ko) 2016-07-01 2019-03-11 하. 룬드벡 아크티에셀스카브 항우울 효과의 신속한 개시를 위한 보티옥세틴 투여 요법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL344331A1 (en) * 1998-05-22 2001-11-05 Lilly Co Eli Combination therapy for treatment of refractory depression
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
US20060293360A1 (en) * 2003-04-04 2006-12-28 H. Lundbeck A/S 4-(2-Phenyloxyphenyl)-piperidine or-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
AU2004226838B8 (en) * 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
DE102006028034A1 (de) * 2006-06-14 2007-12-20 Leifheit Ag Bürste und Kehrgerät mit Bürste
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
TWI405588B (zh) 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter

Also Published As

Publication number Publication date
ES2445400T3 (es) 2014-03-03
US20100144788A1 (en) 2010-06-10
PL2139479T3 (pl) 2013-05-31
WO2008113360A3 (en) 2008-11-13
CN101646438B (zh) 2012-04-11
DK2139479T3 (da) 2013-02-11
RS52676B (en) 2013-06-28
CL2008000796A1 (es) 2008-09-26
UA97660C2 (ru) 2012-03-12
BRPI0808831A2 (pt) 2014-08-26
EP2167085A1 (en) 2010-03-31
CN101674830B (zh) 2012-05-09
RS53138B (en) 2014-06-30
PL2167085T3 (pl) 2014-08-29
AU2008228639B2 (en) 2012-12-13
US20100137366A1 (en) 2010-06-03
KR20090125775A (ko) 2009-12-07
NZ579723A (en) 2011-07-29
ES2399305T3 (es) 2013-03-27
CN101646438A (zh) 2010-02-10
EP2167085B1 (en) 2013-12-25
CA2684556C (en) 2013-01-08
IL200954A0 (en) 2010-05-17
PT2139479E (pt) 2013-02-20
DK2167085T3 (da) 2014-02-03
JP2010521502A (ja) 2010-06-24
MY163537A (en) 2017-09-15
EP2139479B1 (en) 2012-12-12
CY1114774T1 (el) 2016-12-14
HRP20130049T1 (hr) 2013-02-28
TW200848032A (en) 2008-12-16
AR065798A1 (es) 2009-07-01
US8507526B2 (en) 2013-08-13
PT2167085E (pt) 2014-02-17
CA2684556A1 (en) 2008-09-25
JP5388867B2 (ja) 2014-01-15
MX2009009934A (es) 2009-09-24
UA99611C2 (ru) 2012-09-10
EA200970871A1 (ru) 2010-04-30
CY1113965T1 (el) 2016-07-27
EA017407B1 (ru) 2012-12-28
AU2008228639A1 (en) 2008-09-25
IL200954A (en) 2014-12-31
TWI432194B (zh) 2014-04-01
CN101674830A (zh) 2010-03-17
HK1142007A1 (en) 2010-11-26
WO2008113360A2 (en) 2008-09-25
EP2139479A2 (en) 2010-01-06
SI2139479T1 (sl) 2013-04-30

Similar Documents

Publication Publication Date Title
CO6220957A2 (es) 4-2-(4-metilfenilsulfanil-fenil piperidina con inhibicion combinada de recaptacion de serotonina y norepinefrina para el tratamiento del trastorno de deficit de atencion e hiperactividad melancolia depresion resistente al tratamiento o sintomas resid
CO6220962A2 (es) Usos terapeuticos novedosos de 1-[2(2,4-dimetilfenilsulfanil)fenil]-piperazina
HRP20120144T1 (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
AR086356A1 (es) Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
BR112014016085A8 (pt) composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
EA201790406A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
CL2011001927A1 (es) Uso de una composicion farmaceutica de liberacion sostenida, que comprende como ingrediente activo a 4-aminopiridina, que sirve para preparar un medicamento util para el tratamiento de la esclerosis multiple, en dos dosis de 10 miligramos diarias, que permite recuperar la marcha de un paciente afectado.
CO6450649A2 (es) Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazina
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
AR090601A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
CY1118158T1 (el) Δευτεριωμενα 1-πιπεραζινο-3-φαινυλικα ινδανια για τη θεραπευτικη αντιμετωπιση της σχιζοφρενιας
RU2009144846A (ru) Использование модулятора рецептора s1p
BR112014008783A2 (pt) compostos para o tratamento e profilaxia da doença causada por vírus sincicial respiratório

Legal Events

Date Code Title Description
FC Application refused